Inactive Instrument

Highlights Oncobiologics Inc Nasdaq

Equities

US68235M2044

End-of-day quote Nasdaq Other stock markets
- ^USD	-

05-28	Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	MT
05-28	Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Outlook Therapeutics Granted EU Marketing Authorization for Lytenava to Treat Wet AMD	05-28	MT
Outlook Therapeutics, Inc. Receives European Commission Marketing Authorization for LYTENAVA? (bvacizumab grapa) for the Treatment of Wet AMD	05-28	CI
CoStar Group has room for expansion	05-21
Outlook Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	05-15	CI
Outlook Therapeutics Submits Marketing Application for Wet Age-related Macular Degeneration Therapy in UK	05-13	MT
Outlook Therapeutics, Inc. Announces UK Submission of Marketing Authorization Application for ONS-5010 as a Treatment for Wet AMD	05-13	CI
North American Morning Briefing : Stocks Set for -2-	03-28	DJ
Outlook Therapeutics Reports Secondary Share Offering	03-25	MT
Sector Update: Health Care Stocks Ease Late Afternoon	03-22	MT
Sector Update: Health Care Stocks Ease Friday Afternoon	03-22	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	03-22	MT
Outlook Therapeutics Gets EMA Panel Positive Opinion for Wet AMD Treatment -- Shares Rise Pre-Bell	03-22	MT
Outlook Therapeutics Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD	03-22	CI
Outlook Therapeutics to Begin Reverse Stock Split for Regaining Nasdaq Compliance	03-12	MT
North American Morning Briefing : S&P 500 Seen -2-	02-16	DJ
Outlook Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-14	CI
Outlook Therapeutics, Inc. Doses First Subject in Norse Eight	01-31	CI
North American Morning Briefing : Intel Drags Down -2-	01-26	DJ
Outlook Therapeutics Says FDA Clarifies Steps for ONS-5010 Study, Enters Securities Purchase Deals	01-23	MT
Outlook Therapeutics Shares Rally Premarket on ONS-5010 Advances	01-23	DJ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Oncobiologics Inc Nasdaq

Equities

US68235M2044

Highlights

Filters